PMAIP1 and cancer: NOXA has been extensively studied in cancer and proteasome inhibitors have been shown to rely on NOXA for their therapeutic potential indicating that NOXA is a substrate of the ubiquitin–proteasome system (UPS)2,9,10,14,45.